The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model by Beth D. Kirkpatrick, Stephen S. Whitehead,

Slides:

Advertisements

Similar presentations

Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates by Gary Wong, Jason S. Richardson, Stéphane.

Advertisements

Toward Universal Flavivirus Identification by Mass Cataloging

Targeted DNA vaccination induced protection against nasal challenge with influenza virus 14 d after DNA vaccination. Targeted DNA vaccination induced protection.

Long-lasting protection against nasal challenge with influenza virus 252 d after a single DNA vaccination. Long-lasting protection against nasal challenge.

Dengue Antibody and Zika: Friend or Foe?

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 5. Rises in RSV PRNT during the surveillance period.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 7 Correlation of NHP and human ISGs.

Fig. 4. Peanut-specific TH2A cells are specifically targeted during immunotherapy. Peanut-specific TH2A cells are specifically targeted during immunotherapy.

Fig. 1 ZIKV RNA in blood and tissues.

Consolidated Standards of Reporting Trials flow diagram of VRC trial

Fig. 2 Whisker deprivation accelerates and enhances behavioral recovery after right S1FP photothrombosis. Whisker deprivation accelerates and enhances.

Fig. 1. Loss of circadian rhythms in iKO mice.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Filipin staining of marginal gyrus of cerebral cortex in NPC cats

Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 3. Comparison of prediction performance.

Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

Fig. 2. Deficiency of neuronal HS leads to reduced neuroinflammation.

Fig. 3. Improved clinical responses to CD19 CAR-T cell immunotherapy after Cy/Flu lymphodepletion. Improved clinical responses to CD19 CAR-T cell immunotherapy.

Fig. 2. Bacterial/viral score in COCONUT-conormalized whole-blood validation data sets. Bacterial/viral score in COCONUT-conormalized whole-blood validation.

Colonization in tumor models and different modes of administration

Fig. 5. Vitamin B12 supplementation in the host altered the transcriptome of P. acnes in the skin microbiota. Vitamin B12 supplementation in the host altered.

Fig. 7 BMS reduces the elevated expression of type I IFN–regulated genes both ex vivo in blood from patients with lupus and in a phase 1 study of.

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 1. Detection of circulating tumor DNA in CRPC patients.

Fig. 5 Treatment with BMS (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS (PO BID) protects from.

by Joan B. Mannick, Melody Morris, Hans-Ulrich P

The microchip-based drug delivery device and overview of study design

Fig. 5. Octet BLI competition assay using D25 and motavizumab.

Fig. 1 From conventional cuff-based blood pressure measurement to cuff-less BP monitoring using a smartphone. From conventional cuff-based blood pressure.

Opening Up to Precompetitive Collaboration

Fig. 6. Prolonged miR overexpression in the adult heart reduces fibrotic scar size but compromises cardiac function after MI. Prolonged miR

Fig. 2 PK dosing results. PK dosing results. (A) Plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from implanted microchip device.

Fig. 3 Measurement of real-world, high-risk opioid use events.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Representative CT and PET/CT images of three patients with NSCLCs

Fig. 1 Crohn’s disease association within the LRRK2 locus.

Fig. 2 Effect of CSF sTREM2– and CSF sTREM2–to–p-tau181 ratio on changes in cognition. Effect of CSF sTREM2– and CSF sTREM2–to–p-tau181 ratio on changes.

Fig. 8. Purkinje cell quantification and hearing threshold in NPC cats administered IC HPβCD. Purkinje cell quantification and hearing threshold in NPC.

Fig. 2. Overexpression of miR cluster in the developing heart results in increased cardiomyocyte proliferation and cardiomegaly. Overexpression.

by Peter Bacchetti, Steven G. Deeks, and Joseph M. McCune

Evaluation of clinical responses after infusion of CART19 cells

Delineating cancer evolution with single-cell sequencing

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Exposure to SIV in utero results in reduced viral loads and altered responsiveness to postnatal challenge by Chris A. R. Baker, Louise Swainson, Din L.

Fig. 5. High burdens of AA signature mutations and predicted immunogenicity in Taiwan HCCs. High burdens of AA signature mutations and predicted immunogenicity.

Effects of highly concentrated SFN provided as BSE in T2D patients

Making Prospective Registration of Observational Research a Reality

Fig. 1 ZMAb improves survival of EBOV-challenged NHPs

Fig. 3. miR overexpression leads to increased cell proliferation as well as altered differentiation and metabolism in cardiomyocytes. miR

Fig. 3 Anticipated transmission dynamics under scenarios of vaccine escape and vaccine waning. Anticipated transmission dynamics under scenarios of vaccine.

Breakdown of incorrect participant responses.

Fig. 3. Association between peak CTL019 expansion and response.

Fig. 1. APP/PS1;C3 KO mice show improved cognitive flexibility (reversal) compared to APP/PS1 mice at 16 months of age. APP/PS1;C3 KO mice show improved.

Fig. 5. SUS treatment reduces Aβ in a second cohort of AD mice.

Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses. Schematic description of whole-exome or targeted next-generation.

Fig. 1 Isopropanol tolerance variation among E. faecium isolates.

Fig. 4 Gallium increases P. aeruginosa sensitivity to peroxides.

Fig. 8 Immune correlates of protection.

Fig. 3 Postnatal assembly of the humanized gut microbiota.

Neutralizing activity of mAbs isolated from plasmablasts during acute ZIKV infection in DENV-experienced donors. Neutralizing activity of mAbs isolated.

Fig. 6. Connectivity and mobility maps for Lesotho.

Fig. 1. Maps of Lesotho, a landlocked country within South Africa.

Presentation transcript:

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model by Beth D. Kirkpatrick, Stephen S. Whitehead, Kristen K. Pierce, Cecilia M. Tibery, Palmtama L. Grier, Noreen A. Hynes, Catherine J. Larsson, Beulah P. Sabundayo, Kawsar R. Talaat, Anna Janiak, Marya P. Carmolli, Catherine J. Luke, Sean A. Diehl, and Anna P. Durbin Sci Transl Med Volume 8(330):330ra36-330ra36 March 16, 2016 Copyright © 2016, American Association for the Advancement of Science

Fig. 1. Screening, enrollment, and follow-up of flavivirus-seronegative subjects for vaccination with the dengue vaccine TV003 and challenge with DENV-2 6 months later. Screening, enrollment, and follow-up of flavivirus-seronegative subjects for vaccination with the dengue vaccine TV003 and challenge with DENV-2 6 months later. As described in the text, 48 subjects were randomly assigned to receive TV003 or placebo on study day 0. The treatment assignment was masked to study staff and volunteers. On study day 180, all eligible subjects (41) received the challenge virus rDEN2Δ30. PI, principal investigator. Beth D. Kirkpatrick et al., Sci Transl Med 2016;8:330ra36 Copyright © 2016, American Association for the Advancement of Science